IV Injection of Metoclopramide With or Without Dexamethasone

ConditionTrauma Injury
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age16-50
SponsorAhmed Nassar Ibrahim Mohammed

About this trial

Reflux and the aspiration of gastric contents have always been important focal points. Previous study stated that trauma is an important factor in aspiration pneumonia.

Often, emergency trauma patients have residual gastric contents due to the ingestion of food before injury, the accidental swallowing of nasal and/or oral blood after injury, and delayed gastric emptying due to stress, pain, or the use of opioids.

During sedation or general anesthesia, such satiated patients are often at risk of aspiration due to a reduction in lower esophageal sphincter tension and the protective inhibition of the airway reflex.

Perioperative gastric ultrasound can be performed at a bedside ultrasound unit; it can safely, non-invasively, conveniently, and effectively evaluate the fullness of a patient's stomach and the nature of their gastric contents.

It can also be used in the selection of an appropriate method for the anesthetic induction process and can reduce the risk of vomiting, aspiration, and related complications.

As a gastric motility-promoting drug, metoclopramide can accelerate gastric emptying.

Dexamethasone reduced the incidence of nausea and vomiting and improve gastric motility.

Eligibility criteria

Qualifiers

Traumatic patients undergo emergency operations

18-60 years of age

155-180 cm in height

Body mass index <30 kg/m2

Disqualifiers

A history of diseases of important organs, such as diabetes, gastro-paresis, liver and kidney dysfunction, and cardiopulmonary insufficiency.

Contraindications for metoclopramide or dexamethasone treatment.

Taking opioids or drugs that affect gastric motility.

A history of esophageal, gastric, or upper abdominal surgery.

Trial design

Treatments tested in this trial

  • Dexamethasone
  • Ultrasonography assessment

Treatment groups

1 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Ahmed Nassar Ibrahim Mohammed

Lead sponsor

Assiut University

Sponsor institution

Assiut University

Collaborator